StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Other Immunology medicines — U.S. revenue by Quarter

Other Immunology medicines — U.S. revenue ($M) ($M)

QuarterlyAnnual

Eli Lilly Other Immunology medicines — U.S. revenue: $251M in Q2 2026, up 65.1% from a year earlier. That is the highest of the 38 quarters on record here.

Latest, Q2 2026
251
Period ended Jun 30, 2026
Change on a year earlier
+65.1%
152 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Note 2 Disaggregated Revenue.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Immunology medicines — U.S. revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026251+65.1%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026202+98.0%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025187+84.2%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 2025190+102.6%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 2025152+151.7%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025102+103.6%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 2024102-55.0%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 202493.8–Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 202460.4–Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 202450.1–Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023226+1,035.7%Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 202219.9+19,800.0%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-02) ↗

Breakdown

What makes up other Immunology medicines — U.S. revenue

Cite this data

StockData. (2026). Eli Lilly Other Immunology medicines — U.S. revenue ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-other-imm-us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.